TY - JOUR AU - Reddy, S. AU - Raffin, M. AU - Kaklamani, V. PY - 2012 DA - 2012// TI - Targeting angiogenesis in metastatic breast cancer JO - Oncol VL - 17 UR - https://doi.org/10.1634/theoncologist.2012-0043 DO - 10.1634/theoncologist.2012-0043 ID - Reddy2012 ER - TY - JOUR AU - Slamon, D. J. AU - Godolphin, W. AU - Jones, L. A. AU - Holt, J. A. AU - Wong, S. G. AU - Keith, D. E. AU - Levin, W. J. AU - Stuart, S. G. AU - Udove, J. AU - Ullrich, A. PY - 1989 DA - 1989// TI - Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer JO - Science (New York, NY) VL - 244 UR - https://doi.org/10.1126/science.2470152 DO - 10.1126/science.2470152 ID - Slamon1989 ER - TY - JOUR AU - Kumar, R. AU - Yarmand-Bagheri, R. PY - 2001 DA - 2001// TI - The role of HER2 in angiogenesis JO - Semin Oncol VL - 28 UR - https://doi.org/10.1016/S0093-7754(01)90279-9 DO - 10.1016/S0093-7754(01)90279-9 ID - Kumar2001 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Bajamonde, A. AU - Fleming, T. AU - Eiermann, W. AU - Wolter, J. AU - Pegram, M. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Singh, J. C. AU - Jhaveri, K. AU - Esteva, F. J. PY - 2014 DA - 2014// TI - HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development JO - Br J Cancer VL - 111 UR - https://doi.org/10.1038/bjc.2014.388 DO - 10.1038/bjc.2014.388 ID - Singh2014 ER - TY - JOUR AU - Nandikolla, A. G. AU - Rajdev, L. PY - 2016 DA - 2016// TI - Targeting angiogenesis in gastrointestinal tumors: current challenges JO - Transl Gastroenterol Hepatol VL - 1 UR - https://doi.org/10.21037/tgh.2016.08.04 DO - 10.21037/tgh.2016.08.04 ID - Nandikolla2016 ER - TY - JOUR AU - Pegram, M. D. AU - Reese, D. M. PY - 2002 DA - 2002// TI - Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor JO - Semin Oncol VL - 29 UR - https://doi.org/10.1053/sonc.2002.34053 DO - 10.1053/sonc.2002.34053 ID - Pegram2002 ER - TY - JOUR AU - Kerbel, R. S. PY - 2012 DA - 2012// TI - Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer JO - J Mammary Gland Biol Neoplasia VL - 17 UR - https://doi.org/10.1007/s10911-012-9266-0 DO - 10.1007/s10911-012-9266-0 ID - Kerbel2012 ER - TY - JOUR AU - Mackey, J. R. AU - Kerbel, R. S. AU - Gelmon, K. A. AU - McLeod, D. M. AU - Chia, S. K. AU - Rayson, D. AU - Verma, S. AU - Collins, L. L. AU - Paterson, A. H. AU - Robidoux, A. PY - 2012 DA - 2012// TI - Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials JO - Cancer Treat Rev VL - 38 UR - https://doi.org/10.1016/j.ctrv.2011.12.002 DO - 10.1016/j.ctrv.2011.12.002 ID - Mackey2012 ER - TY - JOUR AU - Fuchs, C. S. AU - Tomasek, J. AU - Yong, C. J. AU - Dumitru, F. AU - Passalacqua, R. AU - Goswami, C. AU - Safran, H. AU - Santos, L. V. AU - Aprile, G. AU - Ferry, D. R. PY - 2014 DA - 2014// TI - Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial JO - Lancet (London, England) VL - 383 UR - https://doi.org/10.1016/S0140-6736(13)61719-5 DO - 10.1016/S0140-6736(13)61719-5 ID - Fuchs2014 ER - TY - JOUR AU - Garon, E. B. AU - Ciuleanu, T. E. AU - Arrieta, O. AU - Prabhash, K. AU - Syrigos, K. N. AU - Goksel, T. AU - Park, K. AU - Gorbunova, V. AU - Kowalyszyn, R. D. AU - Pikiel, J. PY - 2014 DA - 2014// TI - Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial JO - Lancet (London, England) VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60845-X DO - 10.1016/S0140-6736(14)60845-X ID - Garon2014 ER - TY - JOUR AU - Tabernero, J. AU - Yoshino, T. AU - Cohn, A. L. AU - Obermannova, R. AU - Bodoky, G. AU - Garcia-Carbonero, R. AU - Ciuleanu, T. E. AU - Portnoy, D. C. AU - Cutsem, E. AU - Grothey, A. PY - 2015 DA - 2015// TI - Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70127-0 DO - 10.1016/S1470-2045(15)70127-0 ID - Tabernero2015 ER - TY - JOUR AU - Mackey, J. R. AU - Ramos-Vazquez, M. AU - Lipatov, O. AU - McCarthy, N. AU - Krasnozhon, D. AU - Semiglazov, V. AU - Manikhas, A. AU - Gelmon, K. A. AU - Konecny, G. E. AU - Webster, M. PY - 2015 DA - 2015// TI - Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.57.1513 DO - 10.1200/JCO.2014.57.1513 ID - Mackey2015 ER - TY - JOUR AU - Holzer, T. R. AU - Fulford, A. D. AU - Nedderman, D. M. AU - Umberger, T. S. AU - Hozak, R. R. AU - Joshi, A. AU - Melemed, S. A. AU - Benjamin, L. E. AU - Plowman, G. D. AU - Schade, A. E. PY - 2013 DA - 2013// TI - Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung JO - PLoS ONE VL - 8 UR - https://doi.org/10.1371/journal.pone.0080292 DO - 10.1371/journal.pone.0080292 ID - Holzer2013 ER - TY - STD TI - Holzer TR, Falcon B, Fulford AD, McDonald S, Ray A, Finnegan P, Uhlik M, Benjamin L, Schade AE, Nasir A. VEGFR2 expression and vascular phenotyping demonstrate different patterns of tumor angiogenesis in human gastric and breast cancers. In: Annual Meeting of the American Association of Cancer Research: 2014; San Diego; 2014. ID - ref15 ER - TY - STD TI - Holzer TR, L ON, Nedderman DM, Fulford AD, Falcon B, Uhlik M, L B, Schade AE, Nasir A. Heterogeneity of vascular endothelial growth factor receptors 1, 2 and 3 in primary human colorectal adenocarcinoma. In: Annual Meeting of the American Association of Cancer Research: April 2014; San Diego; 2014. ID - ref16 ER - TY - STD TI - Holzer TR, Fulford AD, O’Neil L, Nedderman DM, Zhang X, Benjamin L, Schade AE, Nasir A. Heterogeneity of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in human non-small cell carcinomas. In: Annual meeting of the american association for cancer research, Philadelphia; 2015. ID - ref17 ER - TY - STD TI - Holzer TR, Nedderman DM, Nasir A: Robust immunohistochemical assay to characterize human cancer tissues for prevalence of vascular endothelial growth factor receptor 3 (VEGFR3). In: Annual Meeting of the American Association for Cancer Research: 2015; Phildelphia; 2015. ID - ref18 ER - TY - JOUR AU - Nasir, A. AU - Reising, L. O. AU - Nedderman, D. M. AU - Fulford, A. D. AU - Uhlik, M. T. AU - Benjamin, L. E. AU - Schade, A. E. AU - Holzer, T. R. PY - 2016 DA - 2016// TI - Heterogeneity of vascular endothelial growth factor receptors 1, 2, 3 in primary human colorectal carcinoma JO - Anticancer Res VL - 36 ID - Nasir2016 ER - TY - JOUR AU - McShane, L. M. AU - Altman, D. G. AU - Sauerbrei, W. AU - Taube, S. E. AU - Gion, M. AU - Clark, G. M. PY - 2005 DA - 2005// TI - REporting recommendations for tumour MARKer prognostic studies (REMARK) JO - Br J Cancer VL - 93 UR - https://doi.org/10.1038/sj.bjc.6602678 DO - 10.1038/sj.bjc.6602678 ID - McShane2005 ER - TY - JOUR AU - Handerson, T. AU - Camp, R. AU - Harigopal, M. AU - Rimm, D. AU - Pawelek, J. PY - 2005 DA - 2005// TI - Beta 1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-04-2211 DO - 10.1158/1078-0432.CCR-04-2211 ID - Handerson2005 ER - TY - JOUR AU - Elston, C. W. AU - Ellis, I. O. PY - 1991 DA - 1991// TI - Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up JO - Histopathology VL - 19 UR - https://doi.org/10.1111/j.1365-2559.1991.tb00229.x DO - 10.1111/j.1365-2559.1991.tb00229.x ID - Elston1991 ER - TY - BOOK AU - Lakhani, S. R. AU - Ellis, I. O. AU - Schnitt, S. J. AU - Tan, P. H. AU - Vijver, M. J. PY - 2012 DA - 2012// TI - WHO classification of tumours of the breast PB - IARC Press CY - Lyon ID - Lakhani2012 ER - TY - JOUR AU - Smith, N. R. AU - Baker, D. AU - James, N. H. AU - Ratcliffe, K. AU - Jenkins, M. AU - Ashton, S. E. AU - Sproat, G. AU - Swann, R. AU - Gray, N. AU - Ryan, A. PY - 2010 DA - 2010// TI - Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers JO - Clin Cancer Res Off J Am Assoc Cancer Res VL - 16 UR - https://doi.org/10.1158/1078-0432.CCR-09-2797 DO - 10.1158/1078-0432.CCR-09-2797 ID - Smith2010 ER - TY - JOUR AU - Zeileis, A. AU - Kleiber, C. AU - Jackman, S. PY - 2008 DA - 2008// TI - Regression models for count data in R JO - J Stat Softw VL - 27 UR - https://doi.org/10.18637/jss.v027.i08 DO - 10.18637/jss.v027.i08 ID - Zeileis2008 ER - TY - BOOK PY - 2016 DA - 2016// TI - R: A language and environment for statistical computing PB - R Foundation for Statistical Computing CY - Vienna ID - ref26 ER - TY - JOUR AU - Blackwell, K. L. AU - Burstein, H. J. AU - Storniolo, A. M. AU - Rugo, H. AU - Sledge, G. AU - Koehler, M. AU - Ellis, C. AU - Casey, M. AU - Vukelja, S. AU - Bischoff, J. PY - 2010 DA - 2010// TI - Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer JO - J clin oncol Off J Am Soc Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2008.21.4437 DO - 10.1200/JCO.2008.21.4437 ID - Blackwell2010 ER - TY - JOUR AU - Rugo, H. S. AU - Chien, A. J. AU - Franco, S. X. AU - Stopeck, A. T. AU - Glencer, A. AU - Lahiri, S. AU - Arbushites, M. C. AU - Scott, J. AU - Park, J. W. AU - Hudis, C. PY - 2012 DA - 2012// TI - A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer JO - Breast Cancer Res Treat VL - 134 UR - https://doi.org/10.1007/s10549-011-1918-z DO - 10.1007/s10549-011-1918-z ID - Rugo2012 ER - TY - JOUR AU - Baselga, J. AU - Bradbury, I. AU - Eidtmann, H. AU - Cosimo, S. AU - Azambuja, E. AU - Aura, C. AU - Gomez, H. AU - Dinh, P. AU - Fauria, K. AU - Dooren, V. PY - 2012 DA - 2012// TI - Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial JO - Lancet (London, England). VL - 379 UR - https://doi.org/10.1016/S0140-6736(11)61847-3 DO - 10.1016/S0140-6736(11)61847-3 ID - Baselga2012 ER - TY - JOUR AU - Gianni, L. AU - Romieu, G. H. AU - Lichinitser, M. AU - Serrano, S. V. AU - Mansutti, M. AU - Pivot, X. AU - Mariani, P. AU - Andre, F. AU - Chan, A. AU - Lipatov, O. PY - 2013 DA - 2013// TI - AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer JO - J clin oncol Off J Am Soc Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.7912 DO - 10.1200/JCO.2012.44.7912 ID - Gianni2013 ER - TY - JOUR AU - Alameddine, R. S. AU - Otrock, Z. K. AU - Awada, A. AU - Shamseddine, A. PY - 2013 DA - 2013// TI - Crosstalk between HER2 signaling and angiogenesis in breast cancer: molecular basis, clinical applications and challenges JO - Curr Opin Oncol VL - 25 ID - Alameddine2013 ER - TY - JOUR AU - Klos, K. S. AU - Wyszomierski, S. L. AU - Sun, M. AU - Tan, M. AU - Zhou, X. AU - Li, P. AU - Yang, W. AU - Yin, G. AU - Hittelman, W. N. AU - Yu, D. PY - 2006 DA - 2006// TI - ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6 K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-04-4559 DO - 10.1158/0008-5472.CAN-04-4559 ID - Klos2006 ER - TY - JOUR AU - Yang, W. AU - Klos, K. AU - Yang, Y. AU - Smith, T. L. AU - Shi, D. AU - Yu, D. PY - 2002 DA - 2002// TI - ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma JO - Cancer VL - 94 UR - https://doi.org/10.1002/cncr.10553 DO - 10.1002/cncr.10553 ID - Yang2002 ER - TY - JOUR AU - Konecny, G. E. AU - Meng, Y. G. AU - Untch, M. AU - Wang, H. J. AU - Bauerfeind, I. AU - Epstein, M. AU - Stieber, P. AU - Vernes, J. M. AU - Gutierrez, J. AU - Hong, K. PY - 2004 DA - 2004// TI - Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients JO - J clin oncol Off J Am Soc Clin Oncol VL - 10 ID - Konecny2004 ER - TY - JOUR AU - Klos, K. S. AU - Zhou, X. AU - Lee, S. AU - Zhang, L. AU - Yang, W. AU - Nagata, Y. AU - Yu, D. PY - 2003 DA - 2003// TI - Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone JO - Cancer VL - 98 UR - https://doi.org/10.1002/cncr.11656 DO - 10.1002/cncr.11656 ID - Klos2003 ER - TY - JOUR AU - Laughner, E. AU - Taghavi, P. AU - Chiles, K. AU - Mahon, P. C. AU - Semenza, G. L. PY - 2001 DA - 2001// TI - HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression JO - Mol Cell Biol VL - 21 UR - https://doi.org/10.1128/MCB.21.12.3995-4004.2001 DO - 10.1128/MCB.21.12.3995-4004.2001 ID - Laughner2001 ER - TY - JOUR AU - Wen, X. F. AU - Yang, G. AU - Mao, W. AU - Thornton, A. AU - Liu, J. AU - Bast, R. C. AU - Le, X. F. PY - 2006 DA - 2006// TI - HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy JO - Oncogene VL - 25 UR - https://doi.org/10.1038/sj.onc.1209685 DO - 10.1038/sj.onc.1209685 ID - Wen2006 ER - TY - JOUR AU - Xia, W. AU - Gerard, C. M. AU - Liu, L. AU - Baudson, N. M. AU - Ory, T. L. AU - Spector, N. L. PY - 2005 DA - 2005// TI - Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells JO - Oncogene VL - 24 UR - https://doi.org/10.1038/sj.onc.1208774 DO - 10.1038/sj.onc.1208774 ID - Xia2005 ER - TY - JOUR AU - Konecny, G. E. AU - Pegram, M. D. AU - Venkatesan, N. AU - Finn, R. AU - Yang, G. AU - Rahmeh, M. AU - Untch, M. AU - Rusnak, D. W. AU - Spehar, G. AU - Mullin, R. J. PY - 2006 DA - 2006// TI - Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-1182 DO - 10.1158/0008-5472.CAN-05-1182 ID - Konecny2006 ER - TY - JOUR AU - Scaltriti, M. AU - Verma, C. AU - Guzman, M. AU - Jimenez, J. AU - Parra, J. L. AU - Pedersen, K. AU - Smith, D. J. AU - Landolfi, S. AU - Ramon, Y. AU - Cajal, S. AU - Arribas, J. PY - 2009 DA - 2009// TI - Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity JO - Oncogene VL - 28 UR - https://doi.org/10.1038/onc.2008.432 DO - 10.1038/onc.2008.432 ID - Scaltriti2009 ER - TY - JOUR AU - Miller, K. D. AU - Chap, L. I. AU - Holmes, F. A. AU - Cobleigh, M. A. AU - Marcom, P. K. AU - Fehrenbacher, L. AU - Dickler, M. AU - Overmoyer, B. A. AU - Reimann, J. D. AU - Sing, A. P. PY - 2005 DA - 2005// TI - Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer JO - J clin oncol Off J Am Soc Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.05.098 DO - 10.1200/JCO.2005.05.098 ID - Miller2005 ER - TY - JOUR AU - Barrios, C. H. AU - Liu, M. C. AU - Lee, S. C. AU - Vanlemmens, L. AU - Ferrero, J. M. AU - Tabei, T. AU - Pivot, X. AU - Iwata, H. AU - Aogi, K. AU - Lugo-Quintana, R. PY - 2010 DA - 2010// TI - Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer JO - Breast Cancer Res Treat VL - 121 UR - https://doi.org/10.1007/s10549-010-0788-0 DO - 10.1007/s10549-010-0788-0 ID - Barrios2010 ER - TY - JOUR AU - Brown, L. F. AU - Berse, B. AU - Jackman, R. W. AU - Tognazzi, K. AU - Guidi, A. J. AU - Dvorak, H. F. AU - Senger, D. R. AU - Connolly, J. L. AU - Schnitt, S. J. PY - 1995 DA - 1995// TI - Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer JO - Hum Pathol VL - 26 UR - https://doi.org/10.1016/0046-8177(95)90119-1 DO - 10.1016/0046-8177(95)90119-1 ID - Brown1995 ER - TY - JOUR AU - Kranz, A. AU - Mattfeldt, T. AU - Waltenberger, J. PY - 1999 DA - 1999// TI - Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer JO - Int J Cancer J Int Cancer VL - 84 UR - https://doi.org/3.0.CO;2-T DO - 3.0.CO;2-T ID - Kranz1999 ER - TY - JOUR AU - Ryden, L. AU - Linderholm, B. AU - Nielsen, N. H. AU - Emdin, S. AU - Jonsson, P. E. AU - Landberg, G. PY - 2003 DA - 2003// TI - Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer JO - Breast Cancer Res Treat VL - 82 UR - https://doi.org/10.1023/B:BREA.0000004357.92232.cb DO - 10.1023/B:BREA.0000004357.92232.cb ID - Ryden2003 ER - TY - JOUR AU - Ryden, L. AU - Stendahl, M. AU - Jonsson, H. AU - Emdin, S. AU - Bengtsson, N. O. AU - Landberg, G. PY - 2005 DA - 2005// TI - Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response JO - Breast Cancer Res Treat VL - 89 UR - https://doi.org/10.1007/s10549-004-1655-7 DO - 10.1007/s10549-004-1655-7 ID - Ryden2005 ER - TY - JOUR AU - Ghosh, S. AU - Sullivan, C. A. AU - Zerkowski, M. P. AU - Molinaro, A. M. AU - Rimm, D. L. AU - Camp, R. L. AU - Chung, G. G. PY - 2008 DA - 2008// TI - High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer JO - Hum Pathol VL - 39 UR - https://doi.org/10.1016/j.humpath.2008.06.004 DO - 10.1016/j.humpath.2008.06.004 ID - Ghosh2008 ER - TY - JOUR AU - Nakopoulou, L. AU - Stefanaki, K. AU - Panayotopoulou, E. AU - Giannopoulou, I. AU - Athanassiadou, P. AU - Gakiopoulou-Givalou, H. AU - Louvrou, A. PY - 2002 DA - 2002// TI - Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation JO - Hum Pathol VL - 33 UR - https://doi.org/10.1053/hupa.2002.126879 DO - 10.1053/hupa.2002.126879 ID - Nakopoulou2002 ER - TY - STD TI - No authors listed. CDK4/6 inhibition overcomes drug resistance in HER2+ breast cancer. Cancer Discov. 2016, 6(5). ID - ref49 ER - TY - JOUR AU - Goel, S. AU - Wang, Q. AU - Watt, A. C. AU - Tolaney, S. M. AU - Dillon, D. A. AU - Li, W. AU - Ramm, S. AU - Palmer, A. C. AU - Yuzugullu, H. AU - Varadan, V. PY - 2016 DA - 2016// TI - Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors JO - Cancer Cell VL - 29 UR - https://doi.org/10.1016/j.ccell.2016.02.006 DO - 10.1016/j.ccell.2016.02.006 ID - Goel2016 ER - TY - JOUR AU - Witkiewicz, A. K. AU - Cox, D. AU - Knudsen, E. S. PY - 2014 DA - 2014// TI - CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models JO - Genes Cancer VL - 5 ID - Witkiewicz2014 ER - TY - JOUR AU - Roodink, I. AU - Leenders, W. P. PY - 2010 DA - 2010// TI - Targeted therapies of cancer: angiogenesis inhibition seems not enough JO - Cancer Lett VL - 299 UR - https://doi.org/10.1016/j.canlet.2010.09.004 DO - 10.1016/j.canlet.2010.09.004 ID - Roodink2010 ER - TY - JOUR AU - Luu, T. AU - Chung, C. AU - Somlo, G. PY - 2011 DA - 2011// TI - Combining emerging agents in advanced breast cancer JO - Oncol VL - 16 UR - https://doi.org/10.1634/theoncologist.2010-0345 DO - 10.1634/theoncologist.2010-0345 ID - Luu2011 ER -